Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication - PubMed (original) (raw)
Review
. 2012 Dec;99(12):1630-8.
doi: 10.1002/bjs.8895. Epub 2012 Oct 3.
Affiliations
- PMID: 23034699
- DOI: 10.1002/bjs.8895
Review
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication
J W Stevens et al. Br J Surg. 2012 Dec.
Abstract
Background: A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD).
Methods: MEDLINE, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Conference Proceedings, BIOSIS, National Research Register and MetaRegister databases were searched. Eligible studies were randomized controlled trials (RCTs) and published systematic reviews of patients with intermittent claudication due to PAD and whose symptoms persisted despite a period of conservative management. Study selection was conducted by one reviewer with involvement from a clinician. Data were extracted by one reviewer with no blinding to authors or journal, and checked by a second reviewer. Outcome measures were maximum walking distance (MWD) and pain-free walking distance (PFWD).
Results: The review identified 1876 citations; 26 RCTs met the inclusion criteria for the systematic review. Eleven trials provided data relevant for the meta-analysis. Naftidrofuryl oxalate was ranked first for both MWD and PFWD (probability of 0·947 and 0·987, respectively, of being the best treatment) followed by cilostazol and pentoxifylline. For naftidrofuryl oxalate, cilostazol and pentoxifylline, MWD increased by 60 (95 per cent credible interval 20 to 114) per cent, 25 (11 to 40) per cent and 11 (-1 to 24) per cent respectively relative to placebo, and PFWD increased by 49, 13 and 9 per cent.
Conclusion: Naftidrofuryl oxalate and cilostazol are both effective treatments for claudication; naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events.
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Comment in
- Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Stevens JW, et al. Br J Surg. 2013 Dec;100(13):1838-9. doi: 10.1002/bjs.9358. Br J Surg. 2013. PMID: 24227373 No abstract available.
Similar articles
- Cilostazol for intermittent claudication.
Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Bedenis R, et al. Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD003748. doi: 10.1002/14651858.CD003748.pub4. Cochrane Database Syst Rev. 2014. PMID: 25358850 Free PMC article. Updated. Review. - A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G. Squires H, et al. Health Technol Assess. 2011 Dec;15(40):1-210. doi: 10.3310/hta15400. Health Technol Assess. 2011. PMID: 22142554 Free PMC article. Review. - Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G, O'Donnell ME. Meng Y, et al. Angiology. 2014 Mar;65(3):190-7. doi: 10.1177/0003319712474335. Epub 2013 Jan 31. Angiology. 2014. PMID: 23378195 - Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Stevens JW, et al. Br J Surg. 2013 Dec;100(13):1838-9. doi: 10.1002/bjs.9358. Br J Surg. 2013. PMID: 24227373 No abstract available.
Cited by
- Exercise Rehabilitation for Peripheral Artery Disease: A REVIEW.
McDermott MM. McDermott MM. J Cardiopulm Rehabil Prev. 2018 Mar;38(2):63-69. doi: 10.1097/HCR.0000000000000343. J Cardiopulm Rehabil Prev. 2018. PMID: 29465495 Free PMC article. Review. - Cilostazol for intermittent claudication.
Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Bedenis R, et al. Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD003748. doi: 10.1002/14651858.CD003748.pub4. Cochrane Database Syst Rev. 2014. PMID: 25358850 Free PMC article. Updated. Review. - Considerations for Implementation of an Ankle-Foot Orthosis to Improve Mobility in Peripheral Artery Disease.
Bashir AZ, Dinkel DM, Bapat GM, Despiegelaere H, Hassan M, Johanning JM, Pipinos II, Myers SA. Bashir AZ, et al. Arch Rehabil Res Clin Transl. 2021 Jan 5;3(1):100092. doi: 10.1016/j.arrct.2020.100092. eCollection 2021 Mar. Arch Rehabil Res Clin Transl. 2021. PMID: 33778468 Free PMC article. - Clinical and molecular genetics of the phosphodiesterases (PDEs).
Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA. Azevedo MF, et al. Endocr Rev. 2014 Apr;35(2):195-233. doi: 10.1210/er.2013-1053. Epub 2013 Dec 5. Endocr Rev. 2014. PMID: 24311737 Free PMC article. Review. - Ruanjian Qingmai Granules for the Treatment of Early Symptomatic Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Protocol.
Zhang Y, Liu J, Wang Y, Zong Y, Yin K, Cao F, Liang X, Cao Y. Zhang Y, et al. Int J Gen Med. 2024 Oct 11;17:4595-4605. doi: 10.2147/IJGM.S477968. eCollection 2024. Int J Gen Med. 2024. PMID: 39411052 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous